View
217
Download
2
Category
Tags:
Preview:
Citation preview
Administering Treprostinil to an Intubated PatientKristen Merriman, MS, RRT-ACCS, RRT-NPS, AE-C, RCPDirector of Cardiopulmonary & Neurodiagnostic ServicesGood Samaritan Hospital, San José, CA
Rationale
Inhaled treprostinil (Tyvaso®) is FDA approved for treatment of pulmonary hypertension
Rationale
Inhaled treprostinil (Tyvaso®) is FDA approved for treatment of pulmonary hypertension
One unit dose (2.9 mL) is used each day
Rationale
Inhaled treprostinil (Tyvaso®) is FDA approved for treatment of pulmonary hypertension
One unit dose (2.9 mL) is used each day
Patient takes four treatments each day
Rationale
Inhaled treprostinil (Tyvaso®) is FDA approved for treatment of pulmonary hypertension
One unit dose (2.9 mL) is used each day
Patient takes four treatments each day
Proprietary ultrasonic nebulizer
Rationale
Methods
Four 1 mL syringes used to draw up 0.75 mL doses
Methods
Four 1 mL syringes used to draw up 0.75 mL doses
Aerogen nebulizer
Methods
Results
Transient decrease in mean pulmonary arterial pressure (40 mm Hg 36 mm Hg)
Results
Transient decrease in mean pulmonary arterial pressure (40 mm Hg 36 mm Hg)
SpO2 increase (91% 96%)
Recommended